Keybank National Association OH increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 30.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,383 shares of the biopharmaceutical company’s stock after buying an additional 16,569 shares during the period. Keybank National Association OH’s holdings in Royalty Pharma were worth $4,166,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Provenance Wealth Advisors LLC acquired a new stake in Royalty Pharma in the third quarter valued at $26,000. CoreCap Advisors LLC increased its position in Royalty Pharma by 89.2% during the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 413 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Royalty Pharma in the third quarter valued at approximately $62,000. Bessemer Group Inc. increased its holdings in shares of Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 282 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in Royalty Pharma by 263.3% in the 2nd quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 861 shares during the period. 54.35% of the stock is owned by institutional investors.
Analysts Set New Price Targets
RPRX has been the topic of several research analyst reports. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 price objective on shares of Royalty Pharma in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. TD Cowen lifted their target price on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Finally, Morgan Stanley boosted their target price on shares of Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $63.29.
View Our Latest Analysis on Royalty Pharma
Insider Activity
In other news, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 208,252 shares of company stock valued at $12,324,407 in the last ninety days. 18.84% of the stock is currently owned by company insiders.
Royalty Pharma Stock Performance
Shares of NASDAQ:RPRX opened at $69.31 on Monday. The business’s 50 day simple moving average is $61.51 and its 200 day simple moving average is $54.53. Royalty Pharma PLC has a 1 year low of $37.31 and a 1 year high of $70.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29. The company has a market capitalization of $39.76 billion, a P/E ratio of 57.76, a P/E/G ratio of 1.37 and a beta of 0.36.
Royalty Pharma Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is presently 78.33%.
Royalty Pharma Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
